Lesion of the cerebellar noradrenergic innervation enhances the harmaline-induced tremor in rats

Cerebellum

Volumn 10, Issue 2, 2011, Pages 267-280

  Kolasiewicz, Wacław ^a   Kuter, Katarzyna ^a   Nowak, Przemysław ^b   Pastuszka, Agnieszka ^b   Ossowska, Krystyna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Cerebellum; Dopamine; Harmaline; Noradrenaline; Rat; Serotonin; Tremor

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; DESIPRAMINE; DOPAMINE; HARMALINE; NORADRENALIN; OXIDOPAMINE; SEROTONIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CEREBELLUM; CEREBELLUM INJURY; CEREBELLUM VERMIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINE BRAIN LEVEL; DOPAMINERGIC TRANSMISSION; FRONTAL CORTEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMB TREMOR; MALE; NONHUMAN; NORADRENALIN BRAIN LEVEL; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PUTAMEN; RAT; SEROTONIN BRAIN LEVEL; SUBSTANTIA NIGRA;

ADRENERGIC AGENTS; ANIMALS; BRAIN CHEMISTRY; CENTRAL NERVOUS SYSTEM STIMULANTS; CEREBELLUM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; HARMALINE; MALE; NEURAL PATHWAYS; NOREPINEPHRINE; OXIDOPAMINE; RATS; RATS, WISTAR; SEROTONIN; SYNAPTIC TRANSMISSION; TREMOR;

EID: 80051785755     PISSN: 14734222     EISSN: 14734230     Source Type: Journal    
DOI: 10.1007/s12311-011-0250-9     Document Type: Article

References (64)

1. DeLong MR. Possible involvement of central pacemakers in clinical disorders of movement. Fed Proc. 1978;37:2171-5.
2. Deiber M-P, Pollak P, Passingham R, Landais P, Gervason C, Cinotti L, et al. Thalamic stimulation and suppression of parkinsonian tremor. Brain. 1993;116:267-79.
3. Deuschl G, Raethjen J, Baron R, Lindemann M, Wilms H, Krack P. The pathophysiology of parkinsonian tremor: a review. J Neurol. 2000;247 Suppl 5:v/33-48.
4. Timmermann L, Gross J, Dirks M, Volkmann J, Freund HJ, Schnitzler A. The cerebellar oscillatory network of parkinsonian resting tremor. Brain. 2003;126:199-212. (Pubitemid 36068570)
5. Fukuda M, Barnes A, Simon ES, Holmes A, Dhavan V, Giladi N, et al. Thalamic stimulation for parkinsonian tremor: correlation between regional cerebral blood flow and physiological tremor characteristics. Neuroimage. 2004;21:608-15. (Pubitemid 38229923)
6. Rolland A-S, Herrero M-T, Garcia-Martinez V, Ruberg M, Hirsch EC, Francois C. Metabolic activity of cerebellar and basal ganglia-thalamic neurons is reduced in parkinsonism. Brain. 2007;130:265-75. (Pubitemid 46026241)
7. Yang J, Sadler TR, Givrad TK, Maarek J-M, Holschneider DP. Changes in brain functional activation during resting and locomotor states after unilateral damage in rats. Neuroimage. 2007;36:755-73. (Pubitemid 46907632)
8. Yu H, Sternad D, Corcos DM, Vaillancourt DE. Role of hyperactive cerebellum and motor cortex in Parkinson's disease. Neuroimage. 2007;35:222-33. (Pubitemid 46240941)
9. Benninger DH, Thees S, Kollias SS, Bassetti CL, Waldvogel D. Morphological differences in Parkinson's disease with and without rest tremor. J Neurol. 2009;256:256-63.
10. Kizer JS, Palkovits M, Brownstein MJ. The projections of the A8, A9 and A10 dopaminergic cell bodies: evidence for a nigralhypothalamic- median eminence dopaminergic pathway. Brain Res. 1976;108:363-70.
11. Panagopoulos NT, Panagopoulos GC, Matsokis NA. Dopaminergic innervation and binding in the rat cerebellum. Neurosci Lett. 1991;130:208-12.
12. Ikai Y, Takada M, Shinonaga Y, Mizuno N. Dopaminergic and non-dopaminergic neurons in the ventral tegmental area of the rat project, respectively, to the cerebellar cortex and deep cerebellar nuclei. Neuroscience. 1992;51:719-28.
13. Melchitzky DS, Lewis DA. Tyrosine hydroxylase- and dopamine transporter-immunoreactivity axons in the primate cerebellum. Evidence for a lobular- and laminar-specific dopamine innervation. Neuropsychopharmacology. 2000;22:466-72. (Pubitemid 30145614)
14. Samuels ER, Szabadi E. Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part I; principles of functional organization. Curr Neuropharmacol. 2008;6:235-53.
15. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredeci K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004;318(1):121-34. (Pubitemid 39362633)
16. Louis ED, Honig LS, Vonsattel JP, Maraganore DM, Borden S, Moskowitz CB. Essential tremor associated with focal nonnigral Lewy bodies: a clinicopathologic study. Arch Neurol. 2005;62:1004-7. (Pubitemid 40973465)
17. Shill HA, Adler CH, Sabbagh MN, Connor DJ, Caviness JN, Hentz JG, et al. Pathologic findings in prospectively ascertained essential tremor. Neurology. 2008;70:1452-5. (Pubitemid 351521939)
18. Miwa H. Rodent models of tremor. Cerebellum. 2007;6:66-72. (Pubitemid 46410668)
19. Milner TE, Cadoret G, Lessard L, Smith AM. EMG analysis of harmaline-induced tremor in normal and three strains of mutant mice with Purkinje cell degeneration and the role of the inferior olive. J Neurophysiol. 1995;73:2568-77.
20. Wang G, Fowler SC. Concurrent quantification of tremor and depression of locomotor activity induced in rats by harmaline and physostigmine. Psychopharmacology. 2001;158:273-80. (Pubitemid 33071165)
21. Kolasiewicz W, Kuter K, Wardas J, Ossowska K. Role of the metabotropic receptor subtype 1 in the harmaline-induced tremor in rats. J Neural Transm. 2009;116:1059-63.
22. Beitz AJ, Saxon D. Harmaline-induced climbing fiber activation causes amino acid and peptide release in the rodent cerebellar cortex and a unique temporal pattern of Fos expression in the olivo-cerebellar pathway. J Neurocytol. 2004;33:49-74. (Pubitemid 38860219)
23. Paterson NE, Malekiani SA, Foreman MM, Olivier B, Hanania T. Pharmacological characterization of harmaline-induced tremor activity in mice. Eur J Pharmacol. 2009;616:73-80.
24. Sjölund B, Björklund A, Wiklund J. The indoleaminergic innervations of the inferior olive. 2. Relation to harmaline induced tremor. Brain Res. 1977;131:23-7.
25. Yamazaki M, Tanaka C, Takaori S. Significance of central noradrenergic system on harmaline-induced tremor. Pharmacol Biochem Behav. 1979;10:421-7. (Pubitemid 9188092)
26. Mehta H, Saravanan KS, Mohanakumar KP. Serotonin synthesis inhibition in olivo-cerebellar system attenuates harmaline-induced tremor in Swiss albino mice. Behav Brain Res. 2003;145:31-6. (Pubitemid 37188630)
27. Batini C, Buisseret-Delmans C, Conrath-Verrier M. Harmalineinduced tremor and cerebral activities: labeling with 14C-2-deoxyglucose in the rat. CR Acad Sci Hebd Seances Acad Sci D. 1978;287:527-30.
28. Batini C, Buisseret-Delmans C, Conrath-Verrier M. Harmalineinduced tremor. I. Regional metabolic activity as revealed by [14C]2-deoxyglucose in cat. Exp Brain Res. 1981;42:371-82. (Pubitemid 11112366)
29. Miwa H, Nishi K, Fuwa T, Mizuno Y. Differential expression of c- Fos following administration of two tremorgenic agents: harmaline and oxotremorine. NeuroReport. 2000;11:2385-90. (Pubitemid 30622276)
30. Poirier LJ, Sourkes TL, Bouvier G, Boucher R, Carabin S. Striatal amines experimental tremor and the effect of harmaline in the monkey. Brain. 1966;89:37-52.
31. Paxinos G, Watson C. The rat brain. 4th ed. New York: Academic Press; 1998.
32. Ossowska K, Wardas J, Śmiałowska M, Kuter K, Lenda T, Wierońska JM, et al. A slowly developing dysfunction of dopaminergic nigrostriatal neurons induced by long-term paraquat administration in rats: an animal model of preclinical stages of Parkinson's disease. Eur J Neurosci. 2005;22:1294-304. (Pubitemid 41442403)
33. PietraszekM, Michaluk J, Romańska I,Wa̧sik A, Gołembiowska K, Antkiewicz-Michaluk L. 1-Methyl-1, 2, 3, 4-tetrahydroisoquinoline antagonizes a rise in brain dopamine metabolism, glutamate release in frontal cortex and locomotor hyperactivity produced by MK-801 but not the disruptions of prepulse inhibition, and impairment of working memory in rat. Neurotox Res. 2009;16:390-407.
34. Männistö PT, Kaakola S. Catechol-O-methyltrasferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev. 1999;51:593-628.
35. Karai N, Kato T, Katsuyama M, Nakamura M, Katsube J. Effect of L-threo-3, 4-dihydroxyphenylserine (L-threo-DOPS) on brain and serum MHPG levels in mice: evidence for NE formation in CNS. Life Sci. 1987;40:2261-8. (Pubitemid 17086641)
36. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol. 1968;17:1286-97.
37. Curet O, Damoiseau-Ovens G, Sauvage C, Sontag N, Avenet H, Depoortere H, et al. Preclinical profile of befloxatone, a new reversible MAO-A inhibitor. J Affect Disord. 1998;51:287-303. (Pubitemid 29202176)
38. Rommelspacher H, May T, Salewski B. Harman (1-methyl-β- carboline) is a natural inhibitor of monoamine oxidase type A in rats. Eur J Pharmacol. 1994;252:51-9. (Pubitemid 24039458)
39. Curet O, Damoiseau G, Labaune JP, Rovel V, Jarrau FX. Effects of befloxatone, a new potent reversible MAO-A inhibitor, on cortex and striatum monoamines in freely moving rats. J Neural Transm Suppl. 1994;41:349-55. (Pubitemid 24215712)
40. Baum SS, Hill R, Rommelspacher H. Harman-induced changes of extracellular concentrations of neurotransmitters in the nucleus accumbens of rats. Eur J Pharmacol. 1996;314:75-82. (Pubitemid 26378888)
41. Colzi A, D'Agostini F, Cesura AM, Borroni E, Da Prada M. Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo. J Pharmacol Exp Ther. 1993;265:103-11. (Pubitemid 23320949)
42. Adell A, Biggs TA, Myers RD. Action of harman (1-methyl-β- carboline) on the brain: body temperature and in vivo efflux of 5-HT from hippocampus of the rat. Neuropharmacology. 1996;35:1101-7. (Pubitemid 27008185)
43. Llinás R, Yarom Y. Oscillatory properties of guinea-pig inferior olivary neurons and their pharmacological modulation: an in vitro study. J Physiol. 1986;376:163-82. (Pubitemid 16058128)
44. Woodward DJ, Moises HC, Waterhouse BD, Yeh HH, Cheun JE. The cerebellar norepinephrine system: inhibition, modulation, and gating. Prog Brain Res. 1991;88:331-41.
45. Saitow F, Satake S, Yamada J, Konishi S. β-adrenergic receptormediated presynaptic facilitation of inhibitory GABAergic transmission at cerebellar interneuron-Purkinje cell synapses. J Neurophysiol. 2000;84:2016-25.
46. Hirono M, Obata K. a-Adrenoceptive dual modulation of inhibitory GABAergic inputs to Purkinje cells in the mouse cerebellum. J Neurophysiol. 2006;95:700-8. (Pubitemid 44699076)
47. Arshaduddin M, Al Kadasah S, Biary N, Al Deeb S, Al Moutaery K, Tariq M. Citalopram, a selective serotonin reuptake inhibitor augments harmaline-induced tremor in rats. Behav Brain Res. 2004;153:15-20. (Pubitemid 38829284)
48. Arshaduddin M, Kadasah S, Al Deeb S, Al Moutaery K, Tariq M. Exacerbation of harmaline-induced tremor by impramine. Pharmacol Biochem Behav. 2005;81:9-14.
49. Sugihara I, Lang EJ, Llinás R. Serotonin modulation of inferior olivary oscillations and synchronicity: a multiple-electrode study in the rat cerebellum. Eur J Neurosci. 1995;7:521-34.
50. Fernando JC, Hoskins BH, Ho IK. A striatal serotonergic involvement in the behavioral effects of anticholinesterase organophosphates. Eur J Pharmacol. 1984;98:129-32. (Pubitemid 14192546)
51. Mohanakumar KP, Mitra N, Ganguly DK. Tremorogenesis by physostigmine is unrelated to acetylcholinesterase inhibition: evidence for serotonergic involvement. Neurosci Lett. 1990;120:91-3.
52. Sarkar S, Thomas B, Muralikrishnan D, Mohanakumar KP. Effects of serotonergic drugs on tremor induced by physostigmine in rats. Behav Brain Res. 2000;109:187-93. (Pubitemid 30179668)
53. Mehta H, Thomas B, Mohanakumar KP. Effects of pchlorophenylalanine on striatal acetylcholinesterase activity and on biogenic amin levels in nuclei raphe and caudate-putamen during physostigmine-induced tremor in rats. Neurosci Lett. 2001;299:105-8. (Pubitemid 32146356)
54. Salamone JD, Mayorga AJ, Trevitt JT, Cousins MS, Conlan A, Nawab A. Tremulous jaw movements in rats: a model of parkinsonian tremor. Prog Neurobiol. 1998;56:591-611. (Pubitemid 29012460)
55. Carlson BB, Wisniecki A, Salamone JD. Local injections of the 5-hydroxytryptamine antagonist mianserin into substantia nigra pars reticulata block tremulous jaw movements in rats; studies with a putative model of Parkinsonian tremor. Psychopharmacology. 2003;165:229-37. (Pubitemid 36197597)
56. Mehta H, Haobam R, Usha R, Mohanakumar KP. Evidence for the involvement of central serotonergic mechanisms in cholinergic tremor induced by tacrine in Balb/c mice. Behav Brain Res. 2005;163:227-36. (Pubitemid 41138057)
57. Robinson TN, De Souza RJ, Cross AJ, Green AR. The mechanism of tetrahydroaminoacridine-evoked release of endogenous 5-hydroxytryptamine and dopamine from rat brain tissue prisms. Br J Pharmacol. 1989;98:1127-36. (Pubitemid 20011065)
58. Tani Y, Saito K, Tsuneyoshi A, Imoto M, Ohno T. Nicotinic acetylcholine receptor (nACh-R) agonist-induced changes in brain monoamine turnover in mice. Psychopharmacology. 1997;129:225-32. (Pubitemid 27085392)
59. Voogd J, Glickstein M. The anatomy of the cerebellum. Trends Cogn Sci. 1998;2:307-13. (Pubitemid 28396565)
60. Ichinohe N, Mori F, Shoumura K. A di-synaptic projection from the lateral cerebellar nucleus to the laterodorsal part of the striatum via the central lateral nucleus of the thalamus in the rat. Brain Res. 2000;880:191-7.
61. Hoshi E, Tremblay L, Féger J, Carras PL, Strick PL. The cerebellum communicates with the basal ganglia. Nat Neurosci. 2005;8:1491-3. (Pubitemid 41573660)
62. Mason ST, Fibiger HC. Regional topography within noradrenergic locus coeruleus as revealed by retrograde transport of horseradish peroxidase. J Comp Neurol. 1979;187:703-24. (Pubitemid 10227020)
63. Baraban JM, Aghajanian GK. Suppression of firing activity of 5- HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists. Neuropharmacology. 1980;19:355-63. (Pubitemid 10095684)
64. Peyron C, Luppi PH, Fort P, Rampon C, Jouvet M. Lower brainstem catecholamine afferents to the rat dorsal raphe nucleus. J Comp Neurol. 1996;364:402-13. (Pubitemid 26039427)